We aimed to demonstrate whether PET–CT can replace bone marrow biopsy in detecting bone marrow involvement in subtypes of lymphoma. In addition, we aimed to also reveal whether there is a difference between the mean survival of patients with bone marrow involvement via PET–CT or biopsy. A total of 276 newly diagnosed lymphoma patients who underwent bone marrow biopsy and PET–CT prior to the treatment were scanned retrospectively. Bone marrow biopsy was used as the standard method to investigate the presence of bone marrow involvement in PET–CT. The relationship between bone marrow involvement and mean survival was compared using both methods. Out of the 276 patients, bone marrow involvement was detected with PET–CT and with biopsy, respectively in 56 patients (20.2%) and in 78 patients (28.2%). In terms of PET–CT’s accuracy with respect to revealing bone marrow involvement, the highest rates were achieved respectively in diffuse large B cell lymphoma (DLBCL) (87.4%) and Hodgkin lymphoma (HL) (77.7%). In both the PET–CT and bone marrow biopsy methods, Overall Survival (OS) was found to be significantly shorter in patients with involvement than in patients without involvement ( P : 0.001). PET–CT may replace bone marrow (BM) biopsy in detecting the bone marrow involvement in aggressive lymphoma subtypes such as DLBCL and HL. The presence of BM involvement at the time of diagnosis in both PET–CT and BM biopsy is associated with poor prognosis, and OS is short in this group.

中文翻译：

---

骨髓活检和 PET-CT 的骨髓受累比较以及对霍奇金和非霍奇金淋巴瘤患者生存影响的评估


我们的目的是证明 PET-CT 是否可以替代骨髓活检来检测淋巴瘤亚型的骨髓受累情况。此外，我们还旨在通过 PET-CT 或活检揭示骨髓受累患者的平均生存率是否存在差异。共有 276 名新诊断的淋巴瘤患者在治疗前接受了骨髓活检和 PET-CT 回顾性扫描。骨髓活检被用作 PET-CT 中调查骨髓受累情况的标准方法。使用两种方法比较骨髓受累与平均生存率之间的关系。在 276 名患者中，PET-CT 和活检分别检测出 56 名患者（20.2%）和 78 名患者（28.2%）有骨髓受累。就PET-CT显示骨髓受累的准确性而言，弥漫性大B细胞淋巴瘤（DLBCL）（87.4%）和霍奇金淋巴瘤（HL）（77.7%）的准确率最高。在PET-CT和骨髓活检方法中，发现受累患者的总生存期（OS）显着短于未受累患者（P：0.001）。 PET-CT 可以取代骨髓 (BM) 活检来检测侵袭性淋巴瘤亚型（例如 DLBCL 和 HL）的骨髓受累情况。 PET-CT 和 BM 活检诊断时存在 BM 受累与预后不良相关，且该组患者的 OS 较短。